Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1/2 12Phase 2/3 5Phase 3 3Phase 1 2

Status

Completed 115Recruiting 30Terminated 24Unknown 14Active not recruiting 13Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Recurrence 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Oxaliplatin × Clear all
NCT05296005 2025-02-07

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Ohio State University Comprehensive Cancer Center

Phase 1 Withdrawn
Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

NCT02105350 2018-02-19

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

University Health Network, Toronto

Phase 1 Withdrawn
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡